Current Practices in Antibiotic Prophylaxis for Patients on Complement Inhibitors: A Multicenter Survey Across ERN ERKNet Centers

Clicks: 5
ID: 325790
2026
Free PDF
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This article has not been analysed, so there is no overall score — reader engagement is measured and shown alongside.
AI Quality Assessment
Not analyzed
Readership in this journal
Emerging

Ranked #41 of 128 articles by views in clinical kidney journal

Most read Least read

Bar heights use a square-root scale. Only the 120 most-read articles are drawn; the journal has 128 in total.

Mint this article as an NFT
Not yet minted

Create a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.

5 SUSD one-off · no wallet required
Sign in to mint
Abstract
Abstract Background Complement inhibitors such as eculizumab and ravulizumab are increasingly used to treat rare complement-mediated diseases. While effective, these therapies impair host defenses against encapsulated bacteria, leading to a heightened risk of invasive infections. Although vaccination is standard, the role and implementation of antibiotic prophylaxis remain inconsistent across clinical settings. Methods A survey was conducted among European Reference Network for Rare Kidney Diseases (ERN ERKNet) centers to assess current practices regarding antibiotic prophylaxis in patients receiving complement-inhibition therapy. The survey addressed four clinical scenarios—pediatric vs adult, transplant recipient vs non-transplant—and explored three domains: indications for prophylaxis, choice of antibiotic, and duration. Results Twenty-seven centers from 16 European countries participated. Systematic prophylaxis was widely endorsed, particularly for pediatric patients and transplant recipients. Penicillin-class antibiotics were preferred as first-line agents across all groups. In pediatric settings, phenoxymethylpenicillin and amoxicillin were most commonly used, whereas adult regimens included penicillin or fluoroquinolones for those with allergies. Most respondents recommended continuing prophylaxis throughout the duration of complement-inhibition therapy, regardless of vaccination status. The survey revealed areas of heterogeneity in practice, especially regarding allergy management and the duration of post-vaccination coverage. Conclusions This ERKNet survey identifies prevailing practices and variation in antibiotic prophylaxis for patients receiving complement-inhibition therapy. Based on these findings, we propose consensus guidance to support harmonized, risk-adapted prophylaxis strategies across pediatric and adult populations. These guidance statements aim to address an important unmet need in infection prevention among complement-inhibited patients.
Reference Key
openalex_W7203868713 Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors Savino Sciascia, Edoardo Terzolo, Roberta Fenoglio, Dario Roccatello, Stefanie Haeberle, Franz Schaefer, Nicole van de Kar, Marina Vivarelli, the TMA ERN-ERKnet, Małgorzata Stańczyk, Stéphanie Tellier, Marius Miglinas, Ana Teixeira, Rene Andersen, Huib de Jong, Josefina Santos Lascasas, Stathis Tsiakas, Adrian Lungu, Jerome Harambat, Caroline Duineveld, Laurent Mesnard, Luigi Cirillo, Enrique Morales, Giuseppe Grandaliano, Stéphane Decramer, Atif Awan, Ann Raes, Jakub Zieg, M.C. Carratalá, Pedro Arango Sancho, Thomas Simon, Enrique Morales, Ann Raes, Carmen de Lucas Collantes, Nathalie Godefroid, Enrico Vidal, Alena Paříková, Johann Morelle, Cavero Teresa, Miquel Blasco, Evelien Snauwaert, Adrian Lungu, A. Madrid, Martin Konrad
Journal clinical kidney journal
Year 2026
DOI
10.1093/ckj/sfag282
URL
https://doi.org/10.1093/ckj/sfag282
Keywords Keywords not found

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

Comments

No comments yet. Be the first to comment on this article.